Rational Design of a Fibroblast Growth Factor 21-Based Clinical Candidate, LY2405319

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Kharitonenkov, Alexei ^a   Beals, John M ^a   Micanovic, Radmila ^a   Strifler, Beth A ^a   Rathnachalam, Radhakrishnan ^a   Wroblewski, Victor J ^a   Li, Shun ^a   Koester, Anja ^a   Ford, Amy M ^a   Coskun, Tamer ^a   Dunbar, James D ^a   Cheng, Christine C ^a   Frye, Christopher C ^a   Bumol, Thomas F ^a   Moller, David E ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; CYSTINE; FIBROBLAST GROWTH FACTOR 21; HISTIDINE; HYPERGLYCEMIC AGENT; ISOLEUCINE; LEUCINE; LY 2405319; PROLINE; SERINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BIOLOGICAL ACTIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DISULFIDE BOND; DRUG DESIGN; DRUG EFFICACY; DRUG POTENCY; GLUCOSE BLOOD LEVEL; GLYCOSYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; MUTATION; NONHUMAN; OBESITY; PICHIA PASTORIS; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTEIN STABILITY; WEIGHT REDUCTION; YEAST;

3T3 CELLS; AMINO ACID SUBSTITUTION; ANIMALS; CELL LINE; DRUG DESIGN; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; GENETIC VARIATION; HEP G2 CELLS; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MODELS, MOLECULAR; PICHIA; PROTEIN CONFORMATION; PROTEIN STABILITY; RECOMBINANT PROTEINS; TEMPERATURE;

EID: 84874903440     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058575     Document Type: Article

References (38)

1. Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest 115: 1627-1635.
2. Kharitonenkov A, Larsen P, (2011) FGF21 reloaded: challenges of a rapidly growing field. Trends Endocrinol Metab 22: 81-86.
3. IDF (2011) IDF Diabetes Atlas, Fifth Edition. Brussels, Belgium: International Diabetes Federa
4. Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, et al. (2007) The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinology 148: 774-781.
5. Waterham HR, Russell KA, Vries Y, Cregg JM, (1997) Peroxisomal targeting, import, and assembly of alcohol oxidase in Pichia pastoris. J Cell Biol 139: 1419-1431.
6. Higgins DR, Cregg JM, (1998) Introduction to Pichia pastoris. Methods Mol Biol 103: 1-15.
7. Moyers JS, Shiyanova TL, Mehrbod F, Dunbar JD, Noblitt TW, et al. (2007) Molecular determinants of FGF-21 activity-synergy and cross-talk with PPARgamma signaling. J Cell Physiol 210: 1-6.
8. Kharitonenkov A, Dunbar JD, Bina HA, Bright S, Moyers JS, et al. (2008) FGF-21/FGF-21 receptor interaction and activation is determined by betaKlotho. J Cell Physiol 215: 1-7.
9. Maa YF, Hsu CC, (1996) Aggregation of recombinant human growth hormone induced by phenolic compounds. Int J Pharm 140: 155-168.
10. Fransson J, Hallen D, Florin-Robertsson E, (1997) Solvent effects on the solubility and physical stability of human insulin-like growth factor I. Pharm Res. 14: 606-612.
11. Lam XM, Patapoff TW, Nguyen TH, (1997) The effect of benzyl alcohol on recombinant human interferon-gamma. Pharm Res 14: 725-729.
12. Remmele RL Jr, Nightlinger NS, Srinivasan S, Gombotz WR, (1998) Interleukin-1 receptor (IL-1R) liquid formulation development using differential scanning calorimetry. Pharm Res 15: 200-208.
13. Thirumangalathu R, Krishnan S, Brems DN, Randolph TW, Carpenter JF, (2006) Effects of pH, temperature, and sucrose on benzyl alcohol-induced aggregation of recombinant human granulocyte colony stimulating factor. J Pharm Sci 95: 1480-1497.
14. Wang W, Singh SK, Li N, Toler MR, King KR, et al. (2012) Immunogenicity of protein aggregates-concerns and realities. Int J Pharm 431: 1-11.
15. Baase WA, Liu L, Tronrud DE, Matthews BW, (2010) Lessons from the lysozyme of phage T4. Protein Sci 19: 631-641.
16. Nishimura T, Nakatake Y, Konishi M, Itoh N, (2000) Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta 1492: 203-206.
17. Shusta EV, Kieke MC, Parke E, Kranz DM, Wittrup KD, (1999) Yeast polypeptide fusion surface display levels predict thermal stability and soluble secretion efficiency. J Mol Biol 292: 949-956.
18. Micanovic R, Raches DW, Dunbar JD, Driver DA, Bina HA, et al. (2009) Different roles of N- and C- termini in the functional activity of FGF21. J Cell Physiol 219: 227-234.
19. Yie J, Hecht R, Patel J, Stevens J, Wang W, et al. (2009) FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett 583: 19-24.
20. Coskun T, Bina HA, Schneider MA, Dunbar JD, Hu CC, et al. (2008) Fibroblast growth factor 21 corrects obesity in mice. Endocrinology 149: 6018-6027.
21. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58: 250-259.
22. Ogawa Y, Kurosu H, Yamamoto M, Nandi A, Rosenblatt KP, et al. (2007) BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A 104: 7432-7437.
23. Suzuki M, Uehara Y, Motomura-Matsuzaka K, Oki J, Koyama Y, et al. (2008) betaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol Endocrinol 22: 1006-1014.
24. Adams AC, Cheng CC, Coskun T, Kharitonenkov A, (2012) FGF21 requires βklotho to act in vivo. PLoS ONE 7: e49977.
25. Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, et al. (2006) Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444: 770-774.
26. Itoh N, (2010) Hormone-like (endocrine) Fgfs: their evolutionary history and roles in development, metabolism, and disease. Cell Tissue Res 342: 1-11.
27. Chen W, Hoo RL, Konishi M, Itoh N, Lee PC, et al. (2011) Growth hormone induces hepatic production of fibroblast growth factor 21 through a mechanism dependent on lipolysis in adipocytes. J Biol Chem 286: 34559-34566.
28. Ye XL, Gao HS, Wang WF, Ren GP, Liu MY, et al. (2012) [Optimization and characterization of a novel FGF21 mutant]. Yao Xue Xue Bao 47: 897-903.
29. Adams AC, Coskun T, Cheng CC, Gimeno RE, Kharitonenkov A (2012) The breadth of FGF21's metabolic actions are goverened by FGFR1 in adipose tissue. Mol Metab, doi: 101016/jmolmet201208007.
30. Coskun T, Adams AC, DuBois SL, O'Farrell LS, Cheng C, et al. (2012) Fibroblast Growth Factor 21 (FGF21) increases energy expenditure in a leptin-dependent manner. Diabetologia 55: S17.
31. Schmidt FR, (2004) Recombinant expression systems in the pharmaceutical industry. Appl Microbiol Biotechnol 65: 363-372.
32. Cereghino GP, Cregg JM, (1999) Applications of yeast in biotechnology: protein production and genetic analysis. Curr Opin Biotechnol 10: 422-427.
33. Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, et al. (2012) FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61: 505-512.
34. Veniant MM, Komorowski R, Chen P, Stanislaus S, Winters K, et al. (2012) Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153: 4192-4203.
35. Muller TD, Sullivan LM, Habegger K, Yi CX, Kabra D, et al. (2012) Restoration of leptin responsiveness in diet-induced obese mice using an optimized leptin analog in combination with exendin-4 or FGF21. J Pept Sci 18: 383-393.
36. Adams AC, Yang C, Coskun T, Cheng CC, Gimeno RE, et al. (2012) The breadth of FGF21s metabolic actions are governed by FGFR1 in adipose tissue Molecular Metabolism doi.org/10.1016/j.molmet.2012.08.007.
37. Adams AC, Coskun T, Rovira AR, Schneider MA, Raches DW, et al. (2012) Fundamentals of FGF19 & FGF21 action in vitro and in vivo. PLoS One 7: e38438.
38. Moller DE, (2012) Metabolic disease drug discovery- "hitting the target" is easier said than done. Cell Metab 15: 19-24.